Life science company Addlife reports increasing sales in the second quarter compared to the same period last year. Net profit increased. Sales increased 8.0 percent to SEK 2,554 million (2,365). Organic sales growth was 7 percent (8). "It is gratifying to see strong development in the Addlife companies during the second quarter. As expected, Labtech again showed good growth with stable margins. Medtech showed a clear improvement in profitability, driven by the cost reductions that are now producing clear results," writes the company's CEO Fredrik Dalborg. Ebita profit amounted to SEK 299 million (247), with an ebita margin of 11.7 percent (10.4). Profit after tax amounted to SEK 72 million (33), an increase of 118.2 percent compared to the previous year. Earnings per share amounted to SEK 0.60 (0.27), an increase of 122.2 percent compared to the previous year. Cash flow from operating activities amounted to SEK 195 million (82).